HTB | HIV i-Base

UK guide to PrEP now online: major update (2024)

Featured HTB 2024: latest news online 3 January 2024. Related: Editorial.
Glasgow 2024: Double dose start for oral PrEP in new European guidelines – rapid protection in two hours 14 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission, HIV 17 Glasgow 2024.
Liverpool University Drug Interaction website recognised for global impact on research and care 14 November 2024. Related: Conference reports, PK and drug interactions, Treatment advocacy, HIV 17 Glasgow 2024.
Glasgow 2024: Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48 14 November 2024. Related: Conference reports, Antiretrovirals, HIV 17 Glasgow 2024.
Once-weekly oral ART: islatravir plus lenacapavir 48 week results in phase 2 switch study 13 November 2024. Related: Other news.
Glasgow HIV Congress 2024 10 November 2024. Related: Early access, Conference reports, Conference index, HIV 17 Glasgow 2024.
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan 9 November 2024. Related: Early access, Book and film reviews.
WHO toolkit to strengthen engagement of health workers in emergency responses 5 November 2024. Related: On the web.
HTB news: i-Base changes during 2024 1 November 2024. Related: Editorial, Special reports.
Bipolar disorder in people living with HIV 1 November 2024. Related: Early access, Coinfections and complications.
Mpox breakthrough cases after two doses of the MVA-BN vaccine 1 November 2024. Related: Early access, mpox (monkeypox).
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic 1 November 2024. Related: Early access, Treatment access, Paediatric care, Drug resistance.
Future meetings and webinars 2024/2025 1 November 2024. Related: Future meetings.
Confirmed mpox clade 1b case in Germany: risk remains low for EU/EEA 23 October 2024. Related: mpox (monkeypox).
Helsinki Declaration: 2024 edition upholds ethical access to treatment 23 October 2024. Related: Treatment access, HIV prevention and transmission.
Lack of tecovirimat activity against mpox clade 1 21 October 2024. Related: mpox (monkeypox), Coinfections and complications.
Efficacy of MVA-BN vaccine: systematic review 21 October 2024. Related: mpox (monkeypox).
Kidney transplants from HIV positive donors to HIV recipients 17 October 2024. Related: Coinfections and complications, Cancer and HIV.
US NIAID updates HIV guide to person-centred language 17 October 2024. Related: Treatment advocacy, Book and film reviews, On the web.
Long COVID essentials: link to online resources 15 October 2024. Related: On the web, COVID-19.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally 13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission, R4P 2024 Lima.
Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound 9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, R4P 2024 Lima.
Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study 9 October 2024. Related: Conference reports, HIV prevention and transmission, R4P 2024 Lima.
HIVR4P 2024: Context of PrEP in Latin America 7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission, R4P 2024 Lima.
HIVR4P 2024: Introduction 7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission, Conference index, R4P 2024 Lima.
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care 6 October 2024. Related: Special reports.
Mpox outbreak in Australia: half of cases had previously received a vaccine 3 October 2024. Related: mpox (monkeypox).
Gilead announces plans to support generic lenacapavir for low-income countries 2 October 2024. Related: Treatment access.
WHO situation report on mpox 2 October 2024. Related: mpox (monkeypox).
Major update of UK PrEP guidelines online for public consultation 1 October 2024. Related: Special reports, Guidelines, HIV prevention and transmission.
NICE defers decision on CAB-LA as PrEP needing more information 27 September 2024. Related: Treatment access, HIV prevention and transmission.
Second lenacapavir PrEP study protected 99.9% of people in the PURPOSE 2 trial: ACT UP London challenge pricing 26 September 2024. Related: HIV prevention and transmission.
UNAIDS reports debt crisis obstructs HIV response 19 September 2024. Related: Treatment access, Other news.
i-Base library archived at the Bishopsgate Institute and Wellcome Collection 17 September 2024. Related: Treatment advocacy, Other news.
New HIV drug interactions, statin resource and free hybrid workshop 17 September 2024. Related: PK and drug interactions.
UK orders 150,000 doses of MVA-BN mpox vaccine 16 September 2024. Related: mpox (monkeypox).
ART, weight changes and obesity: results from CASCADE cohort 16 September 2024. Related: Side effects, Lipodystrophy and metabolic complications.
Activist pin-up calendar from ACT UP London 11 September 2024. Related: Treatment advocacy, Book and film reviews, Other news.
AIDS 2024: Including people living with HIV in non-HIV research 11 September 2024. Related: Conference reports, Treatment access, Cancer and HIV, Treatment advocacy.
New guidelines for HIV-related lymphoma 3 September 2024. Related: Guidelines.
Responses to mpox clade 1b emergency: webinar details 1 September 2024. Related: mpox (monkeypox).
IAS 2024: Open letter to IAS over online access 1 September 2024. Related: Editorial, Conference reports, World AIDS 25 Munich 2024.
WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study 16 August 2024. Related: mpox (monkeypox).
AIDS 2024: Ten early reports 12 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024 12 August 2024. Related: Antiretrovirals.
Five days on two days off: Biktarvy in pilot FOTO study 12 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
Subcutaneous formulation of long-acting CAB/RPV discontinued 10 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
First data on third-generation integrase inhibitor from ViiV 10 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study 10 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more 29 July 2024. Related: Conference reports, HIV prevention and transmission, World AIDS 25 Munich 2024.
Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines 27 July 2024. Related: Guidelines, HIV prevention and transmission.